HOME > BUSINESS

    BUSINESS

    Nippon Shinyaku’s EGPA Drug Bags Fast-Track Status in US

    September 10, 2025
    Nippon Shinyaku said on September 9 that its JAK1 inhibitor NS-229 has received the US FDA’s fast-track designation for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). NS-229, a JAK1 selective inhibitor originated by Nippon Shinyaku, is designed to suppress…

    To read the full story

    Related Article

    BUSINESS

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
    By Takashi Ebisawa

    The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

    COLUMN

    AI: Your New HR BFF (Not Your Replacement!)
    By Philip Carrigan

    Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

    COMMENTARY

    Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise
    By Koji Shimomura

    Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…